Supplementary Figure S8 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

• DOI: 10.1158/2767-9764.23618593.v1
• Publication Date: 2023-07-03T14:25:02Z
• Authors: Benjamin J Bulen; Nickolay A Khazanov; Daniel H. Hovelson; Laura E Lamb; Marc Matrana; Mark E Burkard; Eddy Shih-Hsin Yang; William J. Edenfield; Elizabeth Claire ...; Adedayo A. Onitilo; Gary L Buchschacher; Alan M Miller; Benjamin M. Parsons; Timothy R. Wassenaar; Jennifer M. Suga; Robert D Siegel; William Irvin; Suresh Nair; Jennifer N. Slim; Jamal Misleh; Jamil Khatri; Gregory A Masters; Sachdev Thomas; Malek M. Safa; Daniel M. Anderson; Jonathan Mowers; Anna C Dusenbery; Stephanie Drewery; Komal Plouffe; Travis Reeder; Hana Vakil; Lynnae Patrias; Amanda Falzetta; Ryan Hamilton; Kat Kwiatkowski; D. Bryan Johnson; Daniel R Rhodes; Scott A. Tomlins

<p>Supplementary Figure S8. shows overlap weighting propensity score analysis of the chemotherapy, anti-PD-(L)1, and chemotherapy + anti-PD-(L)1 validation cohort</p>